top of page

20th Annual Meeting of the
Oligonucleotide Therapeutics Society

Oligonucleotide Therapeutics Society

October 6-9, 2024

Montreal, Canada

Meeting Keynote:

Annemieke Aartsma-Rus

From rare to extremely rare: Applying lessons learned from Duchenne muscular dystrophy antisense oligonucleotide mediated exon skipping to developing individualized treatment.

John Maraganore, PhD

Lifetime Achievement Award 2024

John Maraganore, PhD

Founding CEO & Director
Alnylam Pharmaceuticals 2002-2021


Join leading experts in the field at the OTS Annual Meeting which will feature the latest developments from the various oligonucleotide-based disciplines.

​The Oligonucleotide Therapeutics Society (OTS) Annual Meeting is a forum for the realization of the Society's mission and goals, to foster academic and industry-based research for the development of oligonucleotide therapeutics. The meeting serves as a continuum for dialogue and discussion among industry, academia and health authorities to educate and share progress on the basic research and therapeutic development of oligonucleotides, including antisense, siRNA, immunostimulatory and aptamer applications, RNA/DNA editing and mRNA therapeutics as well as basic RNA research. Leaders in the field from across the globe alongside students (the Next Gen) will present in both general session and poster sessions.

The Annual Meeting is open to anyone interested or involved in oligonucleotide therapeutics. The OTS offers scholarships, awards and travel grants annually. 

For details visit: 

Registration and abstract submissions will open by early May and will be announced via email and social media.

Meeting Committee Chairs:


Committee Members:

 Centre Mont-Royal 


Centre Mont-Royal

OTS will have multiple hotel options with a group rate offering for the 2024 meeting. Check Back Soon!

Hotel Accommodations:

bottom of page